November 17, 2026
congreso-inmunologia

Chylomicronemia from GPIHBP1 autoantibodies

Chylomicronemia from GPIHBP1 autoantibodies

Some instances of chylomicronemia are attributable to autoantibodies in opposition to GPIHBP1, an endothelial cell protein that shuttles lipoprotein lipase (LPL) to the capillary lumen. GPIHBP1 autoantibodies forestall binding and transport of LPL by GPIHBP1, thereby disrupting the lipolytic processing of triglyceride-rich lipoproteins. Right here, we evaluation the “GPIHBP1 autoantibody syndrome” and summarize medical and laboratory findings in 22 sufferers. All sufferers had GPIHBP1 autoantibodies and chylomicronemia, however we didn’t discover a correlation between triglyceride ranges and autoantibody ranges.
Lots of the sufferers had a historical past of pancreatitis, and most had medical and/or serological proof of autoimmune illness. IgA autoantibodies had been current in all sufferers, and IgG4 autoantibodies had been current in 19 of 22 sufferers. Sufferers with GPIHBP1 autoantibodies had low plasma LPL ranges, in line with impaired supply of LPL into capillaries.
Plasma ranges of GPIHBP1, measured with a monoclonal antibody-based ELISA, had been very low in 17 sufferers, reflecting the shortcoming of the ELISA to detect GPIHBP1 within the presence of autoantibodies (immunoassay interference). Nevertheless, GPIHBP1 ranges had been very excessive in 5 sufferers, indicating little capability of their autoantibodies to intrude with the ELISA. Just lately, a number of GPIHBP1 autoantibody syndrome sufferers had been handled efficiently with rituximab, ensuing within the disappearance of GPIHBP1 autoantibodies and normalization of each plasma triglyceride and LPL ranges.
The GPIHBP1 autoantibody syndrome must be thought-about in any affected person with newly acquired and unexplained chylomicronemia. 

congreso-inmunologia
congreso-inmunologia


New molecular foundation related to CD36-negative phenotype within the sub-Saharan African inhabitants

Background: CD36 glycoprotein is expressed by varied cell sorts, together with platelets (PLTs), monocytes, and erythroid precursors, and can also be the receptor for a number of ligands. Nevertheless, absence of CD36 expression appears asymptomatic and is poorly described in Caucasians. In distinction, the frequency reaches 7% and 11% in African Caribbean and Asian individuals, respectively

. Lack of CD36 expression exposes to the chance of immunization in case of being pregnant or PLT transfusion. Two varieties of deficiency have been described: in Sort I, PLTs and monocytes lack CD36 expression and the topics are homozygous or compound heterozygous for CD36 mutations, whereas in Sort II, solely PLTs (Sort IIa), and barely additionally erythroid cells (Sort IIb), are affected. Molecular occasions resulting in Sort II deficiency are poorly understood.

Case report: An African woman, identified with homozygous sickle cell illness and recurrently transfused, was assessed for PLT CD36 expression by immunofluorescence microscopy. The deficiency was then confirmed by monoclonal antibody immobilization of PLT antigen (MAIPA) assay, and the subtype was assessed by move cytometry. The underlying molecular foundation was characterised by DNA sequencing. Moreover, we examined the serum for doable anti-CD36 immunization.

Outcomes and conclusion: Circulate cytometric evaluation on the affected person’s blood samples allowed the analysis of Sort I CD36 deficiency. CD36 antibodies, most likely attributable to her previous historical past of crimson blood cell transfusions, had been recognized by MAIPA and by Luminex expertise assay. Apparently, we recognized via sequencing a brand new molecular foundation concerned in CD36 deficiency: two adenines had been changed by one guanine in Exon 4 (c.367_368delAAinsG) resulting in a cease codon at Place 76.

Rising Methods for Therapeutic Antibody Discovery from Human B Cells

Monoclonal antibodies from human sources are being more and more acknowledged as invaluable choices in lots of therapeutic areas. These antibodies can present beautiful specificity and excessive efficiency whereas sustaining a fascinating security profile, having been matured and tolerized inside human sufferers.
Nevertheless, the invention of those antibodies presents essential challenges, for the reason that B cells encoding therapeutic antibodies might be uncommon in a typical blood draw and are short-lived ex vivo. Moreover, the distinctive pairing of VH and VL domains in every B cell contributes to specificity and performance; due to this fact, sustaining antibody chain pairing presents a throughput limitation.
This work will evaluation the varied approaches aimed toward addressing these challenges with a watch to next-generation strategies for high-throughput discovery from the human B-cell repertoire.
[Linking template=”default” type=”products” search=”CRP (C11F2) Monoclonal Antibody, ALEXA FLUOR 647″ header=”1″ limit=”68″ start=”5″ showCatalogNumber=”true” showSize=”true” showSupplier=”true” showPrice=”true” showDescription=”true” showAdditionalInformation=”true” showImage=”true” showSchemaMarkup=”true” imageWidth=”” imageHeight=””

Leave a Reply

Your email address will not be published. Required fields are marked *